ComputerHunter.org

 

New Antidepressant Developments and Approvals


New antidepressant development, until fairly recently, was at best a random, and at worst a problematic and frustrating, process. Often, medications that were developed for one thing were discovered quite accidentally to have much more important therapeutic effects for a completely different disorder. It has been well described that some of the original antipsychotics were originally developed to assist in anesthesia, and some of the original new antidepressants were originally intended to be medications for tuberculosis or psychosis. New antidepressant development was done on a "chemical" basis; that is, guesses were made as to compounds that would be safe and effective based on chemical structures of established medications. This was very much a trial-and-error process, since very little was known about how these drugs worked and very little could be measured beyond actually giving them to a patient.

New antidepressant development always has been and always will be a partnership between efficacy (ie, whether the drug is effective) and safety (ie, whether the drug can be tolerated by a patient). There were very few ways of knowing the answers to those two questions about any given compound unless you tried it, a process not without its obvious risks. It should be noted that vagus nerve stimulation for depression clearly meets the two main FDA requirements of safety and efficacy.

Medications to treat depression; mild, severe, bipolar, or treatment-resistant, make the news most frequently, and deservedly so. Their progress and approval can potentially benefit almost 8 million Americans who suffer from some form of depression. Because there seems to be more frequency now of depression that is treatment-resistant, meaning most methods of treatment (medications, psychotherapy, electroconvulsive therapy, or a combination of more than one treatment) have failed for a patient, the approval of new antidepressants from companies like Merck, Lilly, and Pfizer, are more important than ever. This is because a new class of medication for treating depression has not been developed in over a decade.

On July 18th, 2005 the FDA approved the first ever treatment long term treatment option for depression; vagus nerve stimulation. You can learn more about this remarkable treatment at http://www.VagusNerveStimulator.com There is a free electronic newsletter to keep you up-to-date.

Charles Donovan was a patient in the FDA investigational trial of vagus nerve stimulation as a treatment for chronic or recurrent treatment-resistant depression. He was implanted with the vagus nerve stimulator in April of 2001. He chronicles his journey from the grips of depression thanks to vagus nerve stimulation therapy in his book:

Out of the Black Hole: The Patient's Guide to Vagus Nerve Stimulation and Depression

The book was exhibited at the American Psychiatric Association's Annual Meeting in May. It is available on his web site and 24 hours a day/7 days a week through the toll free number 1-888-VAGUS-88. If you use discount code FDAYES(all caps), it will save you 25% off the cost of the book and you will get automatic free shipping via U.S. Postal Priority Mail.

The book is also available through Amazon.com and Barnes & Noble.com. The discount does not apply at these two sites.

He is the founder of the http://www.VagusNerveStimulator.com Web Site







Google News - Top Stories

The Associated Press

Markets abroad up on bank rescue hopes
MSN Money - 2 hours ago
Hopeful investors await US bank rescue plan details.Europe-wide bank rescue underway.Central Banks around the world coordinate dollar auctions.
European, Asian markets bounce back The Associated Press
The financial crisis A light at the end of the tunnel? Economist
New Straits Times - Swissinfo - Voice of America - AFP
all 1,042 news articles


Sarah Palin Tones it Down a Notch
ABC News - 38 minutes ago
ABC's Imtiyaz Delawala and Ron Claiborne report: Gov. Sarah Palin significantly ratcheted down the rhetoric in her Sunday evening at an outdoor rally in Rush Run Park in St.
Republicans Fear McCain in Trouble After Hard Week ELECTIONS 2008 RedOrbit
Congressman says McCain sowing 'seeds of hatred' Reuters
Los Angeles Times - Columbus Dispatch - The Associated Press - Lawrence Journal World
all 2,128 news articles


Aljazeera.net

Zimbabwe: Zimbabweans Flood SA As Power-Sharing Deal Troubled
AllAfrica.com - 42 minutes ago
Park station in downturn Johannesburg, South Africa teems with Zimbabweans arriving in the land of plenty in rattled buses that dramatise the escalating economic crisis back home.
Zimbabwe Opposition Leader Threatens to Quit Power-Share Deal Voice of America
Thabo Mbeki to Zimbabwe to mediate new crisis The Associated Press
International Herald Tribune - Bloomberg - Monsters and Critics.com - BBC News
all 2,555 news articles


BBC News

US Move on N. Korea Assailed in Japan
Washington Post - 53 minutes ago
By Blaine Harden TOKYO, Oct. 12 -- A day after the Bush administration removed North Korea from its terrorism blacklist, the country announced that it would resume tearing down its main nuclear plant, and South Korea welcomed the move as a step toward ...
Critics of US-North Korea Nuclear Deal Say US Concedes Too Much Voice of America
North Korea to give UN monitors access to nuclear facilities guardian.co.uk
Reuters - Los Angeles Times - Wall Street Journal - New York Times
all 3,320 news articles


Baltimore Sun

Marek fire 20% contained; 2100 acres burned so far
Los Angeles Times - 3 hours ago
A home and three motor homes have burned, and about 1200 have evacuated. Fire officials say the Angeles National Forest blaze is 'stagnant' but could resurge if winds return.
Video: Fire Burns 500 Acres Northeast of Los Angeles AssociatedPress
Windier, warmer: A recipe for fire Signal
CBS 2 - Los Angeles Daily News - WZTV - MyFox Los Angeles
all 1,335 news articles

Google
 

Copyright © 2006 Computer Hunter - A Division of Arthur´s Job Base